Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on October 28, 2008
JNCI Journal of the National Cancer Institute 2008 100(21):1494-1496; doi:10.1093/jnci/djn402
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/21/1494    most recent
djn402v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Brower, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brower, V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2008.

NEWS

Watchful Waiting Beats Androgen Deprivation Therapy in Early Prostate Cancer

Vicki Brower

The first 150 words of the full text of this article appear below.

Sometimes not treating a patient with cancer may be the best treatment—at least for early prostate cancer, a new study indicates. A retrospective analysis of nearly 20,000 men aged 66 years and older showed that men without aggressive disease who took the "watchful waiting" approach did as well as or better than those who took androgen deprivation therapy (ADT).

ADT is most often used as a palliative treatment for advanced prostate cancer or in patients with early disease who are at high risk of progression. Its routine use in other early-stage patients is frequent but controversial. Commonly prescribed ADT drugs include the gonadotropin-releasing hormone agonists, such as leuprolide and buserelin, and anti-androgens such as flutamide and nilutamide.

In the recent study, Grace Lu-Yao, Ph.D., of the University of Medicine and Dentistry of New Jersey, and colleagues looked at survival rates in more than 19,000 men on Medicare who had not . . . [Full Text of this Article]

Who Benefits?

ADT Use Prevalent

Reasons for Overuse


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?